Company news
ProQR Therapeutics N.V. news in 2024
ProQR Therapeutics N.V.'s news releases, calls and decks from 2024, newest first.
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
December 10, 2024
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
December 9, 2024
ProQR Announces Third Quarter 2024 Operating and Financial Results
November 6, 2024
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
October 24, 2024
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
October 21, 2024
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
October 21, 2024
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
September 9, 2024
ProQR Announces Second Quarter 2024 Operating and Financial Results
August 7, 2024
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
June 17, 2024
ProQR Announces First Quarter 2024 Operating and Financial Results
May 8, 2024
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
May 7, 2024
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
April 22, 2024
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
April 21, 2024
ProQR Announces Year End 2023 Operating and Financial Results
March 12, 2024
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
February 14, 2024
Calls in 2024
Decks in 2024
- Investor Day (December 2024)
Investor day · 78 slides · Dec 11, 2024